Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Frank Buttgereit

Showing results (1-10 of 292) with videos related to

Pageof 30
Sort By:
Annals of the Rheumatic Diseases|September 13, 2011
Do the treatment with glucocorticoids and/or the disease itself drive the impairment in glucose metabolism in patients with rheumatoid arthritis?Frank Buttgereit
Bulletin of the NYU Hospital for Joint Diseases|December 25, 2012
A fresh look at glucocorticoids how to use an old ally more effectivelyFrank Buttgereit
Annals of the Rheumatic Diseases|November 9, 2020
Glucocorticoids: surprising new findings on their mechanisms of actionsFrank Buttgereit
The Lancet. Rheumatology|January 23, 2024
Can we shift the benefit-risk ratio of glucocorticoids?Frank Buttgereit
The Lancet. Rheumatology|January 22, 2024
Getting better at quantifying the toxicity of glucocorticoidsFrank Buttgereit
Nature Reviews. Rheumatology|February 21, 2020
Views on glucocorticoid therapy in rheumatology: the age of convergenceFrank Buttgereit
Zeitschrift Fur Rheumatologie|August 21, 2003
[Selective COX-2 inhibition improves endothelial function in coronary artery disease]Olaf Schultz, Frank Buttgereit
Cellular & Molecular Immunology|January 7, 2022
A new perspective is needed for positive selection of germinal center B cells with higher-affinity B cell receptorsTimo Gaber, Frank Buttgereit
Nature Reviews. Rheumatology|September 4, 2021
GCA management guidelines - vive la différence?Bernhard Hellmich, Frank Buttgereit
Cellular & Molecular Immunology|January 7, 2021
New insights into the fascinating world of glucocorticoids: the dexamethasone-miR-342-Rictor axis in regulatory T cellsFrank Buttgereit, Timo Gaber
Pageof 30

Showing results (1-10 of 292) with videos related to

Sort By:
Pageof 30
Annals of the Rheumatic Diseases|September 13, 2011
Do the treatment with glucocorticoids and/or the disease itself drive the impairment in glucose metabolism in patients with rheumatoid arthritis?Frank Buttgereit
Bulletin of the NYU Hospital for Joint Diseases|December 25, 2012
A fresh look at glucocorticoids how to use an old ally more effectivelyFrank Buttgereit
Annals of the Rheumatic Diseases|November 9, 2020
Glucocorticoids: surprising new findings on their mechanisms of actionsFrank Buttgereit
The Lancet. Rheumatology|January 23, 2024
Can we shift the benefit-risk ratio of glucocorticoids?Frank Buttgereit
The Lancet. Rheumatology|January 22, 2024
Getting better at quantifying the toxicity of glucocorticoidsFrank Buttgereit
Nature Reviews. Rheumatology|February 21, 2020
Views on glucocorticoid therapy in rheumatology: the age of convergenceFrank Buttgereit
Zeitschrift Fur Rheumatologie|August 21, 2003
[Selective COX-2 inhibition improves endothelial function in coronary artery disease]Olaf Schultz, Frank Buttgereit
Cellular & Molecular Immunology|January 7, 2022
A new perspective is needed for positive selection of germinal center B cells with higher-affinity B cell receptorsTimo Gaber, Frank Buttgereit
Nature Reviews. Rheumatology|September 4, 2021
GCA management guidelines - vive la différence?Bernhard Hellmich, Frank Buttgereit
Cellular & Molecular Immunology|January 7, 2021
New insights into the fascinating world of glucocorticoids: the dexamethasone-miR-342-Rictor axis in regulatory T cellsFrank Buttgereit, Timo Gaber
Pageof 30